Related News
Home » Opinion » Chinese Views
Traditional medicine seeks global acceptance
By Yan Hao, Wang Cong and Tian Ying |
July 30, 2010, Friday
|
Print Edition
Print Edition
GUIZHOU Tongjitang Pharmaceutical Co Ltd (TJT) began an ambitious campaign five years ago, evaluating one type of capsule containing traditional Chinese medicine to treat osteoporosis as it sought new drug approval by the United States Food and Drug Administration (FDA).
People were expecting to see a dawning of wider acceptance of traditional Chinese medicines (TCM).Things have not been that simple.
Xu Qian, deputy general manager of the TJT, told Xinhua on Tuesday that the company had not finished their preparations to officially submit its product for clinical trials to the FDA.
"The US criteria for a prescription drug seemed to be too harsh for traditional Chinese medicines. We are not ready yet," he said.
The TJT is promoting a medication that could treat osteoporosis, commonly called bone loss. The drug was made in accordance with a proven mixture from the Miao nationality that has been used for hundreds of years in China.
The TJT is one of the pioneers in the traditional Chinese medicine industry to promote Chinese patent drugs, which are made from Chinese medicinal plants, such as herbs, in foreign markets.
These companies are either in the midst of pre-clinical studies or conducting Phase I and Phase II FDA clinical trials for safety and efficacy verification. Most new drugs finishing Phase III clinical trials can be sold in the US market under the FDA guidelines.
Most of these Chinese drug makers have encountered two major obstacles in the FDA's marathon-like three-phase clinical trials.
One is that theories on composition of Chinese medications and how they work in the human bodies are difficult to explain. The other problem is the huge expense of conducting the trials.
Many traditional Chinese medicines are mixtures of a number of ingredients, which makes them much more difficult to explain than Western drugs in a quantitative analysis.
The efficacy of the Chinese medicines depends on different combinations of those ingredients long-proven by countless human tests and inherited from ancient Chinese physicians. But no one can explain the reasons for mixing those combinations.
"Funds for supporting the clinical trials in the US are our heaviest burden," said Xiao Wei, board chairman of Kanion Pharmaceutical, a TCM manufacturer in China. Kanion is promoting a product that eases discomfort for menstruating women, which is undergoing Phase II trials performed by some 200 volunteer patients. The company will spend about US$300 million if it successfully passes all clinical trials.
Instead of trying to have TCM products registered as medications, some TCM companies in China are seeking another path to promote their products overseas.
Beijing Tongrentang (TRT), a 340-year-old TCM pharmaceutical company, has established at least 38 outlets in Australia, Britain, Japan, the Republic of Korea and some Southeast Asian countries.
The company sent more than 100 Chinese physicians, who are licensed by local authorities, to those TRT stores to allow customers to consult about treatments for diseases.
The TRT's strategy is to foster enthusiasm and trust about traditional Chinese medicines and therapies among foreign patients through the consultations so that foreigners learn to gradually accept Chinese medicines, said Tian Ruihua, the TRT's chief scientist.
"We did not push our traditional Chinese medicines into the FDA's clinical trials early since Westerners would not totally trust our medicines and treatment if they do not fully understand the Oriental culture," Tian told Xinhua. "Production sales in our overseas stores are conducted in absolute compliance with local regulations and laws. We sell them as health foods, dietary supplements and other categories as required by local laws."
Professor Di said another big challenge for traditional Chinese medicines is the consistency of the quality of the medicine's ingredients.
Unlike Western medicines, which are usually made of chemical compounds targeting specific diseases, traditional Chinese medicines rely on materials, mostly medicinal plants, whose quality differs among different batches and production origins.
(The authors are writers at Xinhua news agency.)
People were expecting to see a dawning of wider acceptance of traditional Chinese medicines (TCM).Things have not been that simple.
Xu Qian, deputy general manager of the TJT, told Xinhua on Tuesday that the company had not finished their preparations to officially submit its product for clinical trials to the FDA.
"The US criteria for a prescription drug seemed to be too harsh for traditional Chinese medicines. We are not ready yet," he said.
The TJT is promoting a medication that could treat osteoporosis, commonly called bone loss. The drug was made in accordance with a proven mixture from the Miao nationality that has been used for hundreds of years in China.
The TJT is one of the pioneers in the traditional Chinese medicine industry to promote Chinese patent drugs, which are made from Chinese medicinal plants, such as herbs, in foreign markets.
These companies are either in the midst of pre-clinical studies or conducting Phase I and Phase II FDA clinical trials for safety and efficacy verification. Most new drugs finishing Phase III clinical trials can be sold in the US market under the FDA guidelines.
Most of these Chinese drug makers have encountered two major obstacles in the FDA's marathon-like three-phase clinical trials.
One is that theories on composition of Chinese medications and how they work in the human bodies are difficult to explain. The other problem is the huge expense of conducting the trials.
Many traditional Chinese medicines are mixtures of a number of ingredients, which makes them much more difficult to explain than Western drugs in a quantitative analysis.
The efficacy of the Chinese medicines depends on different combinations of those ingredients long-proven by countless human tests and inherited from ancient Chinese physicians. But no one can explain the reasons for mixing those combinations.
"Funds for supporting the clinical trials in the US are our heaviest burden," said Xiao Wei, board chairman of Kanion Pharmaceutical, a TCM manufacturer in China. Kanion is promoting a product that eases discomfort for menstruating women, which is undergoing Phase II trials performed by some 200 volunteer patients. The company will spend about US$300 million if it successfully passes all clinical trials.
Instead of trying to have TCM products registered as medications, some TCM companies in China are seeking another path to promote their products overseas.
Beijing Tongrentang (TRT), a 340-year-old TCM pharmaceutical company, has established at least 38 outlets in Australia, Britain, Japan, the Republic of Korea and some Southeast Asian countries.
The company sent more than 100 Chinese physicians, who are licensed by local authorities, to those TRT stores to allow customers to consult about treatments for diseases.
The TRT's strategy is to foster enthusiasm and trust about traditional Chinese medicines and therapies among foreign patients through the consultations so that foreigners learn to gradually accept Chinese medicines, said Tian Ruihua, the TRT's chief scientist.
"We did not push our traditional Chinese medicines into the FDA's clinical trials early since Westerners would not totally trust our medicines and treatment if they do not fully understand the Oriental culture," Tian told Xinhua. "Production sales in our overseas stores are conducted in absolute compliance with local regulations and laws. We sell them as health foods, dietary supplements and other categories as required by local laws."
Professor Di said another big challenge for traditional Chinese medicines is the consistency of the quality of the medicine's ingredients.
Unlike Western medicines, which are usually made of chemical compounds targeting specific diseases, traditional Chinese medicines rely on materials, mostly medicinal plants, whose quality differs among different batches and production origins.
(The authors are writers at Xinhua news agency.)
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
